{
    "Trade/Device Name(s)": [
        "Dexcom G7 15 Day Continuous Glucose Monitoring System",
        "Dexcom G7 15 Day CGM System",
        "G7 15 Day"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K243214",
    "Predicate Device Reference 510(k) Number(s)": [
        "K240902"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "KGX"
    ],
    "Summary Letter Date": "February 21, 2025",
    "Summary Letter Received Date": "February 21, 2025",
    "Submission Date": "2025-04-04",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G7 15 Day wearable sensor and transmitter",
        "G7 Mobile Application (iOS or Android)",
        "G7 Receiver"
    ],
    "Method(s)/Technology(ies)": [
        "Continuous glucose sensing",
        "Wire-type sensing mechanism",
        "Wireless communication"
    ],
    "Methodologies": [
        "Continuous measurement",
        "Wireless transmission"
    ],
    "Submission Type(s)": [
        "System",
        "Wearable sensor",
        "Transmitter",
        "Software",
        "Receiver",
        "Mobile application"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G7 15 Day interoperable continuous glucose monitoring system for real-time diabetes management in adults",
    "Indications for Use Summary": "Real-time, continuous glucose monitoring system indicated for management of diabetes in persons 18 years and older, replacing fingerstick testing, aiding in detection of hypo/hyperglycemia, and capable of autonomous communication with automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}